Takeda To Create Wholly Owned Sales Units In Four Countries
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical says it plans to create sales and marketing units in four countries by the end of October. The firm said Belgium, Mexico, Sweden and Turkey are to be the new locations for Takeda wholly owned subsidiaries. The units are to sell the range of Takeda products, including its Actos (pioglitazone) drug for treating diabetes. (Click here for more - a subscription may be required
You may also be interested in...
Turkey's Changing Pharma Market Scene: What Opportunities For MNC Drug Makers?
Situated in one of the globe's most active emerging markets, the Turkish pharmaceutical industry is undergoing fast changes, which could make or break major drug makers, according to Istanbul-based international consulting firm Egon Zehnder International
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.